The DOI matches its Crossref record.
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
Abstract
For the first time, four well‐charac‐ terized compounds from four distinct chemical classes were directly compared for efficacy and potency in bone, uteri, lipids, and adipose tissues in an ovariectomized model with 6 month old rats. Five weeks of oral dosing confirmed that ethynyl estradiol, tamoxifen, and raloxifene are potent inhibitors of the loss in volumetric bone mineral density (BMD, mg/cc) induced by ovariectomy, as measured by computed tomography. In the metaphysis of distal femora from ovariectomized rats, analysis showed a significant 12‐20% decrease (P< 0.01) in the BMD. Linear regression analysis was used to calculate half‐ maximal efficacious doses for ethynyl estradiol ED 50 = 0.04 mg/kg, which was threefold more potent than tamoxifen, which in turn was threefold more potent than raloxifene, which was knore efficacious than nafoxidine. In the uterus, raloxifene had minimal effects on the endometrium and smaller effects on uterine eosinophil peroxidase activity than nafoxidine, tamoxifen, or estrogen, respectively. Estrogen was the most potent in reducing cholesterol levels in ovariectomized rats, whereas tamoxifen and nafoxidine were more effective than raloxifene in blocking gain in body weight. Distinct Compounds had advantages in the management of bone, uterine, serum cholesterol, and adipose tissues after ovariectomy. The distinct pattern of pharnjiacological effects may be best understood in terms of their respective chemical structure, specifically estrogens, ben‐ zothiophenes (raloxifene), dihydronapthylenes (nafoxidine), and triphenylethylenes (tamoxifen). These data point to advantages of Separate compounds in the management of bone, uterine, serum cholesterol, and adipose tissues after estrogen deficiency, and show that the benzothiophene raloxifene has potentially important advantages over estrogen, tamoxifen, or nafoxidine in the uterus.—Sato, M., Rippy, M. K., Bryant, H. U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10, 905‐912 (1996)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Peptide Antagonists of the Human Estrogen Receptor
Norris, J. D., Paige, L. A., Christensen, D. J., Chang, C.-Y., Huacani, M. R., Fan, D., Hamilton, P. T., Fowlkes, D. M., & McDonnell, D. P. (1999) · Science · doi:10.1126/science.285.5428.744 · Cited by 373
Role of estrogens in adipocyte development and function
Cooke, P. S., & Naaz, A. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422901107 · Cited by 370
An, J., Tzagarakis-Foster, C., Scharschmidt, T. C., Lomri, N., & Leitman, D. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100953200 · Cited by 323
Metadata
- Authors
- Sato, M., Rippy, M. K., & Bryant, H. U.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 1996-06
- Volume
- 10
- Issue
- 8
- Pages
- 905-912
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1479966533
- Cited by
- 277
- References
- 0
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. https://app.cochat.ai/papers/10.1096/fasebj.10.8.8666168
- The paper
- Sato, M., Rippy, M. K., & Bryant, H. U. (1996). Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. The FASEB Journal. https://doi.org/10.1096/fasebj.10.8.8666168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.